{"": [104, 1045, 0, 1046, 1068, 0, 1069, 1179, 0, 1180, 2141, 0, 2142, 3580, 0, 3581, 4501, 0, 4502, 5096, 0], "COVID-19 and anti-chemokine antibodies": [5106, 8734, 0], "Anti-chemokine antibodies over time": [8735, 10794, 0], "Anti-chemokine antibodies and severity of disease": [10795, 13923, 0], "Anti-chemokine antibodies and long COVID": [13924, 17306, 0], "Lack of correlation between chemokines and their antibodies": [17307, 19016, 0], "Anti-chemokine antibodies in other infectious and autoimmune diseases": [19017, 20721, 0], "RESULTS": [5097, 20721, 1], "DISCUSSION": [20722, 27851, 0], "COVID-19 original cohort (Lugano):": [27916, 29162, 0], "COVID-19 validation cohort 1 (Milan):": [29163, 29903, 0], "COVID-19 validation cohort 2 (Zurich)15:": [29904, 30855, 0], "Control cohort:": [30856, 31277, 0], "Vaccination cohort:": [31278, 31630, 0], "HIV-1 and autoimmune diseases cohorts:": [31631, 32005, 0], "Lyme disease cohort:": [32006, 32382, 0, 32383, 32571, 0], "Healthy control cohort:": [32572, 33409, 0], "Study participants and ethical approvals": [27874, 33409, 1], "Blood collection, processing, and storage": [33410, 34590, 0], "Peptides:": [34601, 35554, 0], "Proteins:": [35555, 36347, 0], "Reagents": [34591, 36347, 1], "Inhibition of chemotaxis by monoclonal antibodies (Fig. 2f,h; Extended Data Fig. 8g,j):": [37542, 37880, 0], "Inhibition of chemotaxis by plasma purified IgGs (Extended Data Fig. 8k):": [37881, 38599, 0], "Chemotaxis": [36348, 38599, 1], "Lyme disease cohort (Extended Data Fig. 9b):": [41091, 41251, 0], "Reactivity at 6 versus 12 months (Extended Data Fig. 5b,c):": [41252, 41855, 0], "Kinetic of signature anti-chemokine IgG antibodies (Extended Data Fig. 5e):": [41856, 42181, 0], "IgG antibodies binding to SARS-CoV-2 RBD (Figs. 1a and 2b; Extended Data Fig. 4a,c,d; Extended Data Fig. 5b,f; Extended Data Fig. 6c):": [42182, 42795, 0], "ELISA": [38600, 42795, 1], "Chemokine quantification in plasma": [42796, 43227, 0], "Single cell sorting by flow cytometry": [43228, 44750, 0], "Antibody sequencing, cloning, production and purification": [44751, 45969, 0], "Computational analysis of antibody sequences": [45970, 46477, 0], "SARS-CoV-2 pseudotyped reporter virus and neutralization assay": [46478, 47860, 0], "Model interaction between chemokine and chemokine receptor": [47861, 48477, 0], "Tests for statistical significance:": [48500, 49790, 0], "t-SNE:": [49791, 50043, 0], "Clustering:": [50044, 50605, 0], "Logistic regression and additional analyses:": [50606, 52419, 0], "Statistical analysis": [48478, 52419, 1], "MATERIAL AND METHODS": [27852, 52419, 1], "Extended Data": [52420, 52434, 0]}